Lundin, J., Kimby, E., Bjorkholm, M., Celsing, F., Hale, G., Hjalmar, V., Merup, M., Petrescu, A., Tullgren, O., Waldmann, H., Mellstedt, H., & Osterborg, A. (2016). Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL). BLOOD, 98(11), 772A–772A.

Lundin, J., et al. “Phase II Study of Subcutaneous Alemtuzumab (Campath-1H) Therapy of Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL).” BLOOD, vol. 98, no. 11, 2016, pp. 772A–772A.

Lundin, J, E Kimby, M Bjorkholm, F Celsing, G Hale, V Hjalmar, M Merup, et al. 2016. “Phase II Study of Subcutaneous Alemtuzumab (Campath-1H) Therapy of Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL).” BLOOD 98 (11): 772A–772A.